

# SARS-CoV-2 Seroprevalence among People Living with HIV in Ontario:

Findings from the COVID-HIV Evaluation of Serology and Health Services (CHESS) Study

**Freitas C**, Cooper C, Kroch A, Langlois MA, Arbess G, Arnold C, Benoit A, Buchan S, Chambers C, El-Helou P, Hassan H, Kendall C, Knox D, Kwong J, Loutfy M, Mah A, Moineddin R, Moqueet N, Silverman M, Tran V, Walmsley S, Yeung A, Burchell AN for the CHESS Study Team





**33rd Annual Canadian Conference on  
HIV / AIDS Research**

**33<sup>e</sup> Congr s annuel canadien de recherche  
sur le VIH/sida**

## **Conflict of Interest Disclosure**

In the past 2 years I have been an employee of: **University of Toronto**

In the past 2 years I have been a consultant for: **St-Michael's Hospital (Unity Health Toronto)**


In the past 2 years I have received research support (grants) from: **Canadian Immunization Research Network**

There are relationships to disclose: **No**




# SARS-CoV-2 Serologic Testing


- People living with HIV may be at higher risk of SARS-CoV-2 infection and COVID-19 illness
- Many may be infected with SARS-CoV-2 and not experience COVID-19 symptoms
- **Serologic (blood sample) testing:** presence of SARS-CoV-2 antibodies in both **symptomatic** and **asymptomatic** individuals.
- **Seroprevalence:** proportion of the sample that has developed antibodies to SARS-CoV-2 (due to infection and/or vaccination)



**Rationale:** Little is known about SARS-CoV-2 seroprevalence (due to infection and/or vaccination) among people living with HIV within the Canadian context during the Omicron Era




**Objective:** To measure SARS-CoV-2 seroprevalence among people living with HIV in Ontario during the Omicron Era




# Methods

## Participant Recruitment




Up to **1,000** active participants of the Ontario HIV Treatment Network Cohort Study (OCS) were invited between **February 2022 and April 2023**

## Study Procedures




Brief COVID-19 Questionnaire




Dried Blood Spot (DBS) Sample


## Serologic Testing



Testing for the presence of SARS-CoV-2 IgG antibodies against RBD, S, N




# Results Algorithm




SARS-CoV-2 antigens: S = spike protein; RBD = receptor binding domain of spike protein; NP = nucleocapsid protein  
 VAX: self-reported COVID-19 vaccination history (Yes/No)


1 = signal-to-cutoff ratio >1  
 0 = signal-to-cutoff ratio <1

V + I = Humoral Immune Response Due to Vaccination and Previous Infection  
 I = Humoral Immune Response Due to Previous Infection  
 V = Humoral Immune Response Due to Vaccination (previous infection can't be excluded)  
 IND = Indeterminate  
 NE = Negative - No Evident Humoral Immune Response detected (no antibodies detected)



# CHES Recruitment





# CHESS Serology Results

Total Samples:  
476

Immunity due to  
**Vaccination and  
Infection (Hybrid):**

149 (31%)

Immunity due to  
**Vaccination Only:**

308 (65%)

Immunity due to  
**Infection Only  
OR  
No Immunity:**

8 (2%)


**Indeterminate:**

11 (2%)

>96% vaccinated

- $\geq 2$  doses: 100%
- $\geq 3$  doses: 92%






## Characteristics of Hybrid vs Vaccine-Only Groups

	Hybrid (n=149)	Vaccine Only (n=308)	p-value
<b>Age Categories, %</b>			
34 years or less	7	4	0.101
35 to 44 years	19	12	
45 to 54 years	21	23	
55 to 64 years	37	39	
65 year or more	16	23	
<b>Sex, %</b>			
Male	87	88	0.743
Female	13	12	
<b>Race, %</b>			
White	62	76	0.008
Black	18	7	
Latin American	4	5	
Asian (East/South East)	5	4	
Other*	10	8	
<b>Immigration Status, %</b>			
Born in Canada	62	74	0.009
Not Born in Canada	38	26	


\*Other Race includes categories: Arab/West Asian, Indigenous, Multi-race, Other, South Asian (categories combined due to small cells, n<6)



## Characteristics of Hybrid vs Vaccine-Only Groups

	Hybrid (n=149)	Vaccine Only (n=308)	p-value
<b>Occupation Type, %</b>			
Essential Workers*	35	26	0.032
Other Workers	23	19	
Not Working	42	55	
<b>Gross Household Income, %</b>			
<\$20,000	11	18	0.268
\$20,000-\$40,000	18	16	
\$40,000-\$60,000	17	13	
\$60,000-\$80,000	9	11	
\$80,000-\$100,000	9	6	
>\$100,000	26	29	
Prefer not to answer/Don't Know	11	8	
<b>Education Level, %</b>			
Secondary degree or less	21	18	0.356
Post-secondary education	79	82	

\*Essential Worker includes: Hospital or Health Care Facility, First Responder (Paramedic/Firefighter/Police Officer), Childcare Worker, Correctional Officer, Teacher or Other School Staff, Transit Driver, Food Service Industry, Grocery Store, Pharmacy, Hairdresser or Barber, Aesthetician, Flight Attendant, Factory/Warehouse Worker, Self-Identified 'Other Essential Worker' category.



## Essential workers were more likely to be among racialized groups

Race	White	Black	Latin American	Asian (East/South East)	Other Race*
<b>Essential Worker**</b>	36%	64%	50%	55%	44%

\*Other Race includes categories: Arab/West Asian, Indigenous, Multi-race, Other, South Asian (categories combined due to small cells, n<6).

\*\*Essential Worker includes: Hospital or Health Care Facility, First Responder (Paramedic/Firefighter/Police Officer), Childcare Worker, Correctional Officer, Teacher or Other School Staff, Transit Driver, Food Service Industry, Grocery Store, Pharmacy, Hairdresser or Barber, Aesthetician, Flight Attendant, Factory/Warehouse Worker, Self-Identified Other Essential Worker category.




## Limitations

- Sample of people living with HIV engaged in care who volunteered to participate in CHES DBS component → results may not be generalizable to all people living with HIV in Ontario
- Waning anti-N levels over time may be impacting serologic groupings → will be investigated in upcoming analyses



## Conclusions

- Large majority of CHESST participants had vaccine-induced immunity (>96%) → about 1/3 had hybrid immunity
- Those in the hybrid immunity group were more likely to identify as Black, to not be born in Canada, and be essential workers, compared with those with vaccine-induced immunity alone
- Continued monitoring of SARS-CoV-2 seroprevalence among people living with HIV is critical for informing immunization and clinical guidelines, especially as booster vaccines continue to be rolled out and SARS-CoV-2 viral variants continue to evolve



# Acknowledgements

## Nominated Principal Investigator

Ann Burchell, St. Michael's Hospital

## Co-Principal Investigators

Abigail Kroch, OHTN

Curtis Cooper, Ottawa Hospital

Marc-Andre Langlois, UOttawa

## Co-Investigators & Collaborators

Gord Arbess, St. Michael's Hospital

Anita Benoit, Women's College Hospital

Sarah Buchan, PHO

Catharine Chambers, UofT

Claire Kendall, UOttawa

David Knox, Maple Leaf Clinic

Jeff Kwong, ICES

Lawrence Mbuagbaw, McMaster

Rahim Moinheddin, UofT

Nasheed Moqueet, PHAC

Sergio Rueda, CAMH

Vanessa Tran, PHO

Nisha Andany, Sunnybrook Research Institute

Philippe El-Helou, Hamilton Health Sciences Centre

David Knox, Maple Leaf Clinic

Mona Loutfy, Maple Leaf Clinic

Michael Silverman, London Health Sciences Centre

Sharon Walmsley, UHN

John McCullagh

Ron Rosenes

Darien Taylor

## Community Advisory Board members

Muluba Habanyama, Co-Chair

Devan Nambiar, Co-Chair

## PhD Trainees

Catharine Chambers, UofT

Cassandra Freitas, UofT

## Staff

Anna Yeung, St. Michael's Hospital

Ashley Mah, St. Michael's Hospital

Hoda Hassan, St. Michael's Hospital

Judy Needham, CTN

*In memory of Ron Rosenes. We recognize his contributions and leadership of this work.*



COVID-19  
IMMUNITY  
TASK FORCE

GROUPE DE TRAVAIL  
SUR L'IMMUNITÉ  
FACE À LA COVID-19




ONTARIO  
HIV TREATMENT  
NETWORK



the CTN  
CIHR Canadian  
HIV Trials Network



Cassandra Freitas holds a CIRN Trainee Scholarship



**Thank You!**

**Cassandra Freitas:**

Cassandra.Freitas@mail.utoronto.ca